The Expanding Clinical Application of TRK Inhibitors in Cancer Care: A Podcast Series

In this podcast episode, join George D. Demetri, MD, and Alexander Drilon, MD, to learn why, when, and how to test for NTRK fusions in patients with diverse solid tumors.

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Download this short summary slideset based on the content from an expert CCO podcast covering TRK biology and oncogenesis, the frequency of NTRK fusions across diverse tumors, and methods for identifying NTRK fusions in the clinic.

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

In this podcast episode, listen to an engaging discussion between George D. Demetri, MD, and Alexander Drilon, MD, on key clinical trials leading to FDA approvals of first-generation TRK inhibitors, where these agents fit into treatment paradigms for various solid tumors, and considerations for choosing among currently available TRK inhibitors.

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Download this short summary slideset based on the content from CCO podcast with experts discussing key clinical data informing FDA approvals and treatment sequencing with first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC.

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

In this podcast episode, listen to George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to currently approved TRK inhibitors.

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Download this short summary slideset based on the content from a CCO podcast covering key data on second-generation TRK inhibitors that can overcome resistance to first-generation agents in patients with NTRK fusion–positive solid tumors.

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021